Abraxis BioScience Inc. shares continued to slump on Thursday, a day after the biotech drug developer reported a deeper second quarter loss driven by lower revenue and one-time acquisition and litigation charges.

Abraxis said it recorded a loss of $84.1 million, or -$2.10 per share, for the quarter ended June 30, compared with a loss of $14 million (-35 cents) in the same quarter last year. The company recorded a $13.9 million one-time charge for acquisition of Shimoda Biotech and Platco Technologies in April. It also recorded a $58.3 million charge in connection with litigation with Elan Pharmaceutical International Ltd.

Revenue fell 7 percent to $77.6 million. Sales for the main product, the breast cancer treatment Abraxane, fell 6 percent to $73.8 million. The company cited a delay in product orders that had been anticipated for the quarter.

Excluding litigation costs and in-process research and development charges, adjusted earnings were $3.6 million, or 9 cents per share, compared to a loss of $5.6 million (-14 cents) in the same quarter last year.

Abraxis shares closed down 45 cents to $74.45 in Nasdaq trading on Thursday, after falling 4 percent on Wednesday.